Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB) , with antisecretory activity. Vonoprazan inhibits H + ,K + -ATPase activity in porcine gastric microsomes with an IC 50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori [1] [2] [3] .
